Hydroxyethyl starch and its derivatives as nanocarriers for delivery of diagnostic and therapeutic agents towards cancers

Ronghua Tan, Ying Wan *, Xiangliang Yang *

Key Words:
anticancer treatment; chemical modification; diagnostic and therapeutic agents; hydroxyethyl starch; nanocarriers; prodrug

ABSTRACT

Many types of drugs and agents used for cancer diagnosis and therapy often have low bioavailability and insufficient efficacy, as well as causing various side effects due to their nonspecific delivery. Nanocarriers with purposely-designed compositions and structures have shown varying degrees of abilities to deliver these compounds towards cancers in passive or active manners. Despite the availability of a variety of materials for the construction of nanocarriers, natural polymers with good biocompatibility and biodegradability are preferable for such usage because of their high in vivo safety as well as easy removal of degradation products. Among the natural polymers intended for building nanocarriers, hydroxyethyl starch and its derivatives have gained tremendous attention in the field of drug delivery in the form of nanomedicines over the last decade. There is growing optimism that ever more hydroxyethyl starch-based nanomedicines will be a significant addition to the armoury currently used for cancer diagnosis and therapy.

Introduction

Cancer is one of the most destructive diseases with high incidences and death rates. Cancer occurrence is correlated with quite a variety of factors such as culture, social intercourse, lifestyle, and living environment as well as hormonal and genetic aspects. The growing global prevalence of cancer has made cancer diagnosis and therapy one of the most investigated aspects over the last decade. Despite the varied types of therapeutic modalities available for cancer treatments so far, each of them has some associated side effects or certain limitations. Chemotherapy based on cytotoxic drugs is one of the principal strategies applied to malignancies to date. However, direct administration of chemotherapeutic drugs often causes severe adverse effects on normal tissues whether it is used alone or in combination with surgery, radiation therapy, or biological therapy. Since the administration of small molecule anticancer drugs in a free formulation has some drawbacks, chiefly including short half-life in blood circulation, nonspecific delivery and systemic toxicity, a wide variety of drug delivery systems, as an alternative to direct administration of these drugs, have now been developed to reduce their side effects while improving their bioavailability.

Drug delivery systems in the form of nanocarriers can deliver encapsulated drugs with several distinct benefits, such as improved solubility, prolonged plasma half-life, and reduced side effects. The desirable nanocarrier should have certain characteristics: (I) well-defined structures for stably and efficiently entrapping drugs; (II) the ability for endosomal escape; and (III) ability to release the encapsulated drugs at the target sites in response to intracellular environmental changes. To meet these requirements, a large number of nanocarriers with specifically-designed structures and functions have been constructed so far for delivering different drugs, aiming at prolonging their circulation in the bloodstream, improving their cancer targeting and reducing their systemic toxicity. In the case of polymeric nanocarriers, the utilised excipients need to be biodegradable because the accumulation of nondegradable excipients inside human tissues or organs could result in long-term toxicity. Among varied types of excipient materials,
polysaccharides have mainly been used to fabricate nanocarriers for
delivering diagnostic and therapeutic agents owing to their unique
biocompatible and biodegradable properties.\textsuperscript{12, 13}

Hydroxyethyl starch (HES) is a semisynthetic polysaccharide obtained
by hydroxyethylation of amylopectin, and it has been used as a
plasma expander for years.\textsuperscript{14} HES has several meritorious properties,
such as biocompatibility, biodegradability, non-toxicity, excellent
water solubility, and very low hypersensitivity.\textsuperscript{15, 16} Additionally, HES
contains a lot of functional groups, allowing convenient chemical
modification to construct nanocarriers with favourable structures and
multi-functionalities.\textsuperscript{17, 18} In recent years, many investigations on HES-
based nanomedicines have been conducted, and growing evidence
supports the hypothesis that HES and its derivatives have superior
potential in acting as promising nanocarriers for delivering
diagnostic and therapeutic agents towards cancers.\textsuperscript{15-20}

**Starch and its Hydroxyethyl Derivatives**

**Starch**

As a type of carbohydrate, starch is produced by many different
living plants via photosynthesis. The innate starch has two kinds
of chain structures, linear and branched, commonly referred to as
amylose and amylopectin (Figure 1A and B).\textsuperscript{21} Amylose is composed
of glucosyl units that are linearly linked by \( \alpha-(1-4) \)-linkages in
approximately 99\% of bonds and \( \alpha-(1-6) \)-linkages in around 1\%,
and has a molecular weight in a range between \( 1 \times 10^5 \) and \( 1 \times 10^6 \)
Da. These structural characteristics make amylose poorly soluble
in water.\textsuperscript{18, 21} Amylopectin contains approximately 95\% \( \alpha-(1-4) \)-
linkages and 5\% \( \alpha-(1-6) \)-linkages and has its molecular weight
ranging between \( 1 \times 10^7 \) and \( 1 \times 10^9 \) Da.\textsuperscript{18, 21} Despite its multiple
uses, the poor solubility in cooled water and fast degradation rate
of native starch have limited its utilization in nanomedicines.\textsuperscript{16, 19, 21, 22}

To circumvent the limitations of native starch, many efforts have
been directed toward modifying starch via grafting, oxidation, and
esterification to achieve desirable starch derivatives and expand
their applications.\textsuperscript{14, 15, 17-20}

![Figure 1](image1.png)

**Figure 1.** (A, B) Chemical structures of amylose (A) and amylopectin (B). (C) Possible substitution patterns of
hydroxyethyl modification in the glucosyl unit of starch. (D) Chemical structures of HES.

**Hydroxyethyl starch (HES)**

HES is a starch derivative prepared by reacting amylopectin
with ethylene oxide in alkaline media.\textsuperscript{14} Amylopectin is
structurally similar to glycogen, a branched glucose-storage
human polysaccharide, which may be the reason for the non-
immunogenicity of HES.\textsuperscript{16, 20} As far as a single glucosyl unit is
concerned, hydroxyethyl modification could occur on its C-2, C-3,
and C-6 sites, as illustrated in Figure 1C. In the case of HES, the
hydroxyethyl substitution predominantly takes place at C-2 sites
of the glucosyl units, as hydrolysis at the C-2 sites is notably slower
than that which occurs at the C-6 sites.\textsuperscript{23} The hydroxyl groups at the
C-3 sites of the glucosyl units have much lower activity compared
to that at C-2 or C-6 sites,\textsuperscript{23} and thus, hydroxyethyl modification
mainly takes place at the C-2 and C-6 sites of the glucosyl units
in HES, as shown in Figure 1D. Hydroxyethyl modification of
amylopectin plays key roles in regulating the solubility of the
amylopectin and its degradation rate,\textsuperscript{24} and accordingly, causes
HES to become water-soluble at ambient temperature and its \( \alpha \)-amylose-mediated degradation is also markedly reduced
in comparison to the unmodified amylopectin. HES is often
categorised into different classes basing on a few typical parameters,
such as molecular weight, mole substitution, and substitution
pattern (C-2/C-6 substitution ratio) of hydroxyethyl groups, and
these parameters are closely correlated to the pharmacokinetics of
HES.\textsuperscript{24} Various types of HES products have been produced since
the first generation of HES became commercially available.\textsuperscript{20}
Nowadays, HES is widely used as a pharmaceutical excipient
for regular drugs or as a designed carrier for nanomedicines in
the form of prodrugs, particles, micelles, and vesicles.\textsuperscript{14, 18-20}

The major reason why HES has become a favourite carrier
material is mainly attributed to its following advantages:\textsuperscript{14, 15} (1)
good water solubility and protein repellent nature against certain
opsonins such as immunoglobulins, fibrinogen, and complement
proteins, allowing HES nanocarriers to evade rapid clearance from
the bloodstream; (2) very low hypersensitivity; (3) significantly prolonged retention time in the blood plasma and certain organs as compared to the native starch; and (4) largely improved stability of HES due to the degradation resistance of hydroxethyl groups.

Investigations into the pharmaceutical application of HES began many years ago. A landmark event was a clinical study on the intravascular volume expansion properties of HES in the 1970s. With the rapid development of nanomedicines in the last decade, HES has attracted a lot of clinical attention. HES contains a large number of free hydroxyl groups, which enables HES to be chemically modified in designed manners. Among diverse HES derivatives, many of them have shown great potential in acting as nanocarriers for the delivery of diagnostic and therapeutic agents toward cancers.

Polymeric Prodrugs
Characteristics of polymeric prodrugs
Polymeric prodrugs are a type of polymer–drug conjugate that is commonly built by covalently binding small molecule drugs onto a polymer backbone. Prodrugs were primarily proposed through the Ringsdorf model that hypothetically consists of three major components: (1) a biocompatible polymer backbone with a highly hydrophilic nature to achieve well-defined dispersivity and stability of the conjugated drugs in the aqueous medium; (2) a drug bound to the polymeric backbone with a covalent linkage; and (3) a specific moiety with designated functions to potentially interact with particular molecules or cells. Based on this model, prodrugs can offer several explicit advantages over traditional small molecule drugs. The aqueous solubility changes of many drugs when administered as prodrugs significantly improve their efficacy since 40–60% of regular drugs in development have low aqueous solubility, and in turn, exhibit poor bioavailability. Prodrugs also offer the opportunity to moderate the release of the conjugated drug by tailoring the structure and properties of the prodrug main chain. By doing so, the rate and duration of drug delivery might be regulated in custom-designed ways while avoiding undesired side effects which could arise from large fluctuations in concentration unavoidable with periodic drug administration. Prodrugs can also modulate drug pharmacokinetics, which would be beneficial for certain drugs having a short plasma half-life or showing off-target toxicities. In addition to the mentioned benefits, prodrugs could be capable of delivering the loaded drug towards the site of pharmacological action given that they carry targeting moieties.

It is known that many anticancer drugs have poor water solubility and metabolic instability, and their usage in the clinic is very often limited due to their low efficacy and dose-dependent toxicity. In clinical cancer therapy, a general goal for administering an anticancer drug is to deliver it at a dose high enough to attain high cytotoxicity against cancer cells. Nevertheless, the actual applied drug dose has to be limited to minimise the toxicity to normal tissues and organs. A previous study on solid tumours pointed out that in comparison to small molecule drugs, uptake of macromolecular drugs, usually in the form of nanoparticles (NPs), would be increased due to the enhanced permeability and retention (EPR) effect arising from a combination of poor lymphatic drainage and increased vascular permeability in the tumour microenvironment. Accordingly, polymeric prodrugs usually exhibit a much greater capability to accumulate at the tumour site through the EPR effect when compared to their small-molecule drug counterparts, making them attractive in cancer diagnosis and therapy. Besides the EPR effect, an alternative route associated with tumour uptake of nanomedicine has recently been proposed based on the transcytosis effect observed from a kind of γ-glutamyl transpeptidase-responsive camptothecin-polymer conjugate. When the conjugate comes into contact with the tumour blood vessels or extravasates into the tumour interstitium, its γ-glutamyl moieties are cleaved by the overexpressed γ-glutamyl transpeptidase on the cell membrane, and accordingly, the conjugate becomes positively charged, which is quite conducive to the endocytosis of the conjugate due to its cationic character. The resulting conjugate is thus able to efficiently penetrate into the tumour via caveolae-mediated endocytosis and transcytosis. This bioresponsive strategy has potential for the development of therapeutic polymers to treat different diseases based on physiological signals.

Hydroxyethyl starch-based prodrugs for anticancer treatment
HES is particularly attractive for prodrug development because it has full water solubility, tunable degradation without lengthy accumulation in the body, and good systemic tolerability. In addition, HES can be administered at a high daily dose and contains numerous functional groups, making it an excellent candidate for prodrug construction. Many efforts have now been made to develop HES-based prodrugs for anticancer treatments. Several first-line anticancer chemotherapeutic drugs, as shown in Figure 2, have been used together with HES to build different prodrugs, and the resulting prodrugs show greatly improved anticancer efficacy compared to free drugs with varying degrees of potency in clinical translation.

A doxorubicin (DOX) prodrug (HES-SS-DOX) was constructed by conjugating DOX onto HES through a redox-sensitive disulphide bond linkage for delivering DOX and reducing its side effects. The disulphide bond linkage was designed in response to glutathione (GSH) considering that the intracellular GSH level of tumour cells can be several times higher than that of normal cells. The in vivo examination of HES-SS-DOX prodrug demonstrated that the GSH-mediated antitumor performance was much better than free DOX whilst the free DOX-associated cardiotoxicity was greatly reduced. A similar method with some modifications in chemical reaction routes was also used to construct a type of HES-SS-paclitaxel (PTX) prodrug by replacing DOX in HES-SS-DOX with PTX, and so creating the HES-SS-PTX prodrug which was further self-assembled into stable NPs with a monodispersed characteristic. It was found that after intravenous administration, the HES shell of HES-SS-PTX NPs was degraded to varying degrees by α-amylase in the bloodstream. As a result, the size of the HES-SS-PTX NPs became smaller with increased circulation time, facilitating extravasation of HES-SS-PTX NPs out from blood vessels and their penetration deep into the tumour interstitium. Results obtained from in vivo experiments revealed that HES-SS-PTX NPs showed several advantages over Taxol, a commercially-available anticancer drug, and had potential for further clinical development. It is worth mentioning that the structure, property
and performance of the disulphide-linked prodrugs are affected to varying degrees by disulphide-bearing linkers. Some studies on disulphide-linked prodrugs indicated that the linker length played an important role in the self-assembling process of the prodrugs; and moreover, the linkage sites and the type of linkers also exerted strong influences on the performance of the prodrugs. These findings are meaningful for effectively designing disulphide-involved prodrugs.

5-Fluorouracil (5-FU) is commonly used in chemotherapeutic treatment for different malignant tumours. To reduce its side effects, a 5-FU derivative, 5-fluorouracil-1-acetic acid (fUAC), was conjugated onto HES to prepare a HES-fUAC prodrug through an esterification reaction between the hydroxyl groups in HES and the carboxyl groups in fUAC. The in vitro experimental results revealed that by exposing the HES-fUAC prodrug to human plasma or rat plasma, only fUAC release was detected and there were no significant differences measured from the fUAC release profiles. However, when exposed to rat liver homogenate, the HES-fUAC prodrug would release both fUAC and 5-FU, but the release rate of fUAC was seen to be much faster than that of 5-FU. Under in vivo administration conditions, only fUAC was released from the HES-fUAC prodrug. The in vivo performance evaluation indicated that the group administered the HES-fUAC prodrug exhibited a much higher peak fUAC plasma concentration and a greatly prolonged fUAC plasma half-life when compared to the group administered free fUAC, suggesting that the pharmacokinetics of fUAC were greatly improved by use of the HES-fUAC prodrug.

10-Hydroxy camptothecin (10-HCPT) is one of the camptothecin analogues, and shows a wide variety of anticancer activities against different solid tumours. Nevertheless, several drawbacks of 10-HCPT, including low aqueous solubility, short plasma half-life, and dose-dependent toxicity, hamper its clinical application. In an attempt to overcome these, 10-HCPT was conjugated onto HES via a covalent linkage between the carboxyl groups in the succinic anhydride-modified HES and the amino groups in the glycine spacer on the modified 10-HCPT to form a 10-HCPT-HES prodrug. Testing in vivo revealed that the 10-HCPT-HES prodrug was able to overcome the disadvantages of 10-HCPT and had greatly enhanced anticancer efficacy in a Hep-3B-tumor-bearing nude mouse model.

Methotrexate (MTX) is an antifolate drug and is commonly used for the treatment of certain cancers, rheumatoid arthritis, and other diseases. Methotrexate was therefore connected to HES to create a HES-MTX prodrug via an esterification reaction between the hydroxyl groups in glucosyl units of HES and the activated carboxyl groups of MTX through the pre-constructed carbodiimide adducts. The HES-MTX prodrug looked like a type of NP with a negatively-charged surface that is somewhat similar to the surface of the vascular endothelium in terms of the charging property. The small size and the negative surface charge of HES-MTX prodrugs may result in their longer half-life in plasma, and consequently, their increased tumour accumulation via the EPR effect. The study on the HES-MTX prodrug once again demonstrates that HES is an excellent candidate for constructing polymeric prodrugs. In order to reduce the liver toxicity associated with MTX chemotherapy, an effort was also made to build methoxy poly(ethylene glycol) (PEG)/oleic acid prodrug micelles with physical encapsulation of MTX. Such designed nanomedicines were found to exhibit superior anti-tumour efficacy without inducing adverse effects in liver owing to the co-delivery of a hepatoprotective prodrug and MTX.

Hydroxychloroquine (HCQ) is a 4-aminoquinoline derivative, and was previously used as a common antimalarial agent. Hydroxychloroquine has recently been conjugated onto HES via a carboxydiimidazole coupling route to prepare a chloroquine-modified HES prodrug (CQ-HES) with a developed ability to inhibit the invasion of pancreatic cancer cells. CQ-HES prodrugs displayed the propensity to assemble into NPs in a pH-dependent manner, and...
the resulting CQ-HES NPs were demonstrated to have a greatly enhanced ability to inhibit the migration and invasion of pancreatic cancer cells when compared to free HCQ. No significant HCQ release was detected from CQ-HES prodrugs, suggesting that the activity against pancreatic cancer cells was explicitly attributed to the action of CQ-HES instead of HCQ. Considering the promising ability to block cancer cell invasion and the ability to form NPs, this CQ-HES prodrug has potential for future clinical application.

Recently, a large variety of polymeric prodrugs have been developed using regular covalent linkages. In addition, some sensitive linkages with responsiveness to various stimuli such as pH, light, heat, magnetism and enzymes have also been introduced into prodrugs to imbue them with improved capabilities. Several HES-based prodrugs constructed with environmentally-responsive linkages or with active targeting functionalities have been developed to achieve improved anticancer efficiency as well as reduced side effects.

A type of DOX-bound prodrug was created by linking DOX to HES via a hydrazine (Hyd) bond to attain pH-sensitivity (HES-Hyd-DOX). The HES-Hyd-DOX was synthesised via a multi-step reaction route. HES was first modified with nitrophenyl chloroformate and then with Hyd monohydrate to produce an intermediate (HES-NHNH₂). DOX was further reacted with HES-NHNH₂ to obtain HES-Hyd-DOX prodrugs, followed by the formation of HES-Hyd-DOX NPs via self-assembly. The intracellular acid-trigged disassociation of HES-Hyd-DOX NPs was detected, and the conjugated DOX was released from HES-Hyd-DOX NPs in a controllable manner with improved anticancer efficacy when compared to free DOX.

Another type of DOX-conjugated HES prodrug with pH-sensitivity was synthesised through a one-step synthesis route using oxidised HES, DOX, and a cyclopeptide (cRGD) (denoted as HES-DOX/cRGD). This HES-DOX/cRGD prodrug contained Schiff base linkages between DOX and HES whilst carrying cRGD moieties. HES-DOX/cRGD prodrugs showed confirmed ability to self-assemble into NPs with the cRGD moieties protruding outward from their surface. The optimally-fabricated HES-DOX/cRGD NPs showed improved ability to deliver DOX to tumours through the interaction between cRGD and its receptor αvβ3 integrin overexpressed on the membrane of certain tumour cells.

In addition to HES-Hyd-DOX and HES=DOX/cRGD prodrugs, HES has also been modified with luteinizing hormone-releasing hormone (LHRH) while carrying DOX to generate HES-Dox/HLRH prodrugs with active targeting features. It is known that LHRH membrane receptors are overexpressed in many types of cancer cells associated with prostate, breast, ovarian and endometrial tumours. Besides, LHRH receptors are also found in both metastatic lymph nodes and lesions of prostate cancer. Importantly, LHRH receptor expression is scarce in normal tissues.

Thus, HES-Dox/LHRH would be capable of delivering DOX targeted at cancer cells by way of LHRH-receptor mediated active targeting with improved anti-tumour efficacy. Indeed, HES-Dox/LHRH prodrugs have been demonstrated to have higher levels of anti-tumour and anti-metastasis activities based on the RM-1 xenografted mouse model while having lower systemic toxicity in comparison to free DOX and non-targeted HES-DOX, suggesting their potential for clinical translation.

Cis-platinum (CP) is a widely-used chemotherapeutic drug which has been used to treat a range of cancers since it was approved by the FDA in 1978. A CP-conjugated HES prodruk functionalised with lactobionic acid (LA; a galactose (Gal) moiety) was fabricated into NPs (LA-HES-Pt) for the actively-targeted delivery of CP. The asialoglycoprotein receptor is known to be usually overexpressed on certain hepatic carcinoma cells such as HepG-2 or H22 cells. Since Gal can bind specifically to the asialoglycoprotein receptor, LA-HES-Pt NPs can thus deliver CP toward hepatic carcinoma cells. In vitro experiments confirmed that LA-HES-Pt NPs can efficiently target HepG-2 cancer cells and promote cellular endocytosis while exerting much stronger effects on cancer cells compared to free CP.

Based on the above observations, it can be seen that these HES-based anticancer prodrugs differ markedly in their composition, structure, property and performance. To facilitate the identification of the main differences between these prodrugs, several of their characteristics are summarised in Table 1.
designated laser irradiation were able to fully eradicate tumours with only one injection and one single subsequent laser irradiation on the tumour site during a 14-day treatment period. In addition, they showed almost no impairment to the body.

The third method for the preparation of HES-based NPs is to graft some hydrophobic polymer side chains onto HES, and the obtained amphipathic HES grafting copolymers are further fabricated into NPs.27, 35, 58

**Nanoparticles fabricated with amphipathic Hydroxyethyl starch copolymers**

In general, the size of NPs has a critical impact on their performance. Large NPs with sizes of approximately 300 nm or larger would be likely to be detained by the reticuloendothelial system (RES) in liver and spleen, while small NPs with sizes less than 200 nm are more capable of accumulating in a tumour via the EPR effect.3 A partial and temporary RES blockade strategy was proposed, using HES-grafted-polylactide (HES-g-PLA) copolymer NPs to enhance DOX delivery toward tumors.27 In this strategy, large empty HES-g-PLA NPs (mean size: approximately 700 nm) were used to temporarily block up RES in tumour-bearing mice for a certain period of time before the administration of small DOX-loaded HES-g-PLA NPs (mean size: approximately 130 nm), as illustrated in Figure 4. Based on this sequential administration mode, the DOX-loaded HES-g-PLA NPs were able to effectively deliver DOX specifically toward tumours.

In the case of chemotherapy for solid tumours, heterogeneous

---

**Table 1. HES-based polymeric prodrugs and their characteristics**

| Name of prodrug | Name of drug | Responsiveness | Linkage | Strength | Reference |
|-----------------|--------------|----------------|---------|----------|-----------|
| HES-SS-DOX      | DOX          | Redox          | Disulphide bond | Responsive release; Improved efficiency; Reduced side effects | Hu et al.30 |
| HES-SS-PTX      | PTX          | Enzyme/Redox   | Disulphide bond | Responsive release; Enhanced penetration; Improved efficiency; Reduced side effects | Li et al.29 |
| HES-FUAC        | 5-FU         | –              | Ester bond    | Improved efficiency; Reduced side effects | Luo et al.40 |
| 10-HCPT-HES     | 10-HCPT      | –              | Amide bond    | Improved efficiency; Reduced side effects | Li et al.46 |
| HES-MTX         | MTX          | –              | Ester bond    | Improved efficiency; Reduced side effects | Goszczyński et al.17 |
| CQ-HES          | HCQ          | –              | Ester bond    | Improved efficiency; Reduced side effects | Sleightholm et al.13 |
| HES-Hyd-DOX     | DOX          | pH             | Hydrazine bond | Responsive release | Zhu et al.51 |
| HES-DOX         | DOX          | pH             | Imine bond    | Targeting; Improved efficiency; Reduced side effects | Li et al.15 |
| HES-DOX/cRGD    | DOX          | pH             | Imine bond    | Targeting; Improved efficiency; Reduced side effects | Li et al.45 |
| HES-DOX/LHRH    | DOX          | pH             | Imine bond    | Targeting; Improved efficiency; Reduced side effects | Zhao et al.46 |
| LA-HES-Pt       | Pt           | –              | Ester bond    | Improved efficiency; Reduced side effects | Xiao et al.32 |

Note: 10-HCPT: 10-hydroxy camptothecin; 5-FU: 5-fluorouracil; CQ: chloroquine; cRGD: cyclopeptide; DOX: doxorubicin; HCQ: hydroxychloroquine; HES: hydroxyethyl starch; Hyd: hydrazine; LHRH: luteinizing hormone-releasing hormone; MTX: methotrexate; PTX: paclitaxel.

---

**Figure 3.** Schematic illustration for the construction of DiR/HES-SS-PTX NPs (DHP). DiR: 1,1-dioctadecyl-3,3,3,3-tetramethyl indotricarbocyanine iodide; HES: hydroxyethyl starch; NPs: nanoparticles; PTX: paclitaxel.
distribution of a drug inside the tumour is ubiquitous because tumours usually create certain pathological barriers to prevent drugs from approaching tumour cells. Hence, tumour cells in regions of low or sublethal concentration of therapeutics would be hardly eradicated.\textsuperscript{35, 54} Besides the possibly of causing neoplasm relapse, such sublethal or insufficient chemotherapy could also result in tumour metastasis via an epithelial–mesenchymal transition (EMT) mechanism.\textsuperscript{35, 55} Considering the fact that transforming growth factor-β (TGF-β) plays a vital role in the EMT via interactions between TGF-β and its receptor, LY2157299, a TGF-β receptor inhibitor was co-delivered together with DOX using HES-g-PLA NPs as a vehicle, as shown schematically in Figure 5, to suppress the inadequate chemotherapy-promoted metastasis. The results demonstrate that the co-delivery of DOX and LY2157299 is an effective strategy to achieve this goal.\textsuperscript{35} An \textit{in vivo} study on mice bearing subcutaneous 4T1 tumours revealed that the co-delivery of DOX and LY2157299 simultaneously suppressed primary tumour, with a tumour inhibition rate of 80.7\%, and distant metastasis.

HES has also been grafted with polycaprolactone (PCL) to create an amphiphilic copolymer (HES-PCL). The achieved HES-PCL was further functionalised with Gal to fabricate DOX/ICG-loaded nanocolloidosomes (NCs), as illustrated in Figure 6.\textsuperscript{34} Such fabricated NCs thus obtained Gal-mediated targeting capability via interaction between Gal and asialoglycoprotein receptors. The functionalised DOX/ICG@Gal-HES-PCL NCs were found to have a densely-packed structure, and their shell-like surface was composed of arranged hydrophilic HES NPs. \textit{In vivo} results indicated that DOX/ICG@Gal-HES-PCL NCs had tumour-targeting ability and were able to fully eradicate tumours through chemo-photothermal combination therapy.

### Hydroxyethyl starch-involved nanocarriers

PEG is a water-soluble, biocompatible and non-immunogenic polymer which is widely used as the hydrophilic segment for modifying different hydrophobic polymers. Nowadays, PEGylation serves as an important technique to prolong the circulation time of certain NPs and to control their dosing interval.\textsuperscript{59} However, this technique has raised several concerns. It has been reported that high intracellular PEG accumulation can alter organelle density, and concomitantly, give rise to variations in the activity of lysosomal enzymes and transporters as well as membrane glycoproteins due to the nondegradable nature of PEG.\textsuperscript{59, 60} Furthermore, the increased stability of NPs as a result of PEGylation could impede the escape of drugs from endosomes in tumour cells, resulting in reduced efficacy.

In an attempt to circumvent the “PEG dilemma”, HES has been explored as a substitute for modification of NPs.\textsuperscript{61-64} HESylation was compared with PEGylation on the same base using polydopamine (PDA) NPs as the core material and DOX as the
Hydroxyethyl starch used for anticancer nanomedicines

model drug since PDA is biodegradable with many advantageous properties. PDA NPs were first prepared and they were then modified with thiolated HES and aminated PEG to create HES-PDA NPs and PEG-PDA NPs. These NPs were loaded with DOX to finally obtain DOX@HES-PDA NPs and DOX@PEG-PDA NPs, respectively, as schematised in Figure 7. In vivo experiments revealed that HESylated PDA NPs were similar to PEGylated PDA NPs, with characteristics including good stability, high drug loading efficiency, favourable lyophilization stability, biocompatibility, and tumour inhibition rate.

In some cases, HES was modified with certain hydrophobic small molecules, and was further fabricated into nanocarriers to enhance the delivery of diagnostic and therapeutic agents. One of such modified HES derivatives was synthesised by conjugating 1-octadecanethiol (C18) onto the backbone of HES via a redox-sensitive disulphide bond linkage, and the achieved HES-SS-C18 was subsequently connected to an iRGD peptide as branches. This specifically synthesised iRGD HES-SS-C18 was self-assembled into nanoclusters with reduction-responsive disintegratable features for delivering DOX, as illustrated in Figure 8. DOX@iRGD-HES-SS-C18 nanoclusters were demonstrated to have an ability to deliver DOX towards tumours through iRGD-mediated blood vessel targeting while showing enhanced tumour penetration.

Figure 6. Schematic illustration of the structure of DOX/ICG-loaded Gal-HES-PCL nanocolloidosomes and their pickering emulsion formation. DOX: doxorubicin; Gal: galactose; HES: hydroxyethyl starch; ICG: indocyanine green; PCL: polycaprolactone.

Figure 7. Schematic illustration showing the preparation of DOX@HES-PDA NPs and DOX@PEG-PDA NPs. DOX: doxorubicin; HES: hydroxyethyl starch; mPEG: methoxy poly(ethylene glycol); NPs: nanoparticles; PDA: polydopamine; PEG: poly(ethylene glycol).

Figure 8. Schematic illustration of the fabrication of DOX@iRGD-HES-SS-C18 NCs. C18: 1-octadecanethiol; DOX: doxorubicin; HES: hydroxyethyl starch; iRGD: 9-amino acid cyclic peptide; NC: nanoclusters.
Another hydrophobically-modified HES derivative was developed by conjugating oleic acid (OA) onto the glucosyl units of HES, and the synthesised HES derivative (HES-OA) was self-assembled into ICG-loaded NPs (ICG@HES-OA) to achieve improved photodynamic therapy.66 By co-delivering ICG@HES-OA NPs and β-phenylethyl isothiocyanate, a compound which depletes GSH, it was found that ICG@HES-OA NPs exhibited efficient singlet oxygen generation under laser irradiation, promoted cellular uptake, and enhanced tumour accumulation, whilst β-phenylethyl isothiocyanate showed a significant intracellular GSH depletion effect, suggesting that such combination therapy holds potential for clinical translation due to their synergistic antitumor effects.66

A type of HES-involved micelle was fabricated using a hydrophobically-modified HES derivative. HES was first modified with propynyl glycidyl ether to produce an intermediate with hydrophobic branches (PyHES), and PyHES was further connected with N-acetyl-cysteine (NAC) through a thiol-yne click reaction to produce an intermediate with hydrophobic branches (PyHES). PyHES-NAC was able to self-assemble into micelles in response to changes in pH values. PyHES-NAC micelles were found to have the ability to protect the drug under acidic conditions while rapidly releasing the drug under neutral conditions.67

HES was first esterified with lauric, palmitic, and stearic acids to achieve a PyHES-NAC derivative with pH-responsive features.67 PyHES-NAC micelles were demonstrated to have significantly enhanced antioxidant and anticancer activity compared to free NAC owing to the improved solubility and stability of NAC.

TG100-115 is an exclusive phosphatidylinositol 3-kinase-γ inhibitor, which plays an important role in the progression of different tumours by reversing the phenotype of tumour-associated macrophages.71 TG100-115 was conjugated onto HES, followed by connection with CDM-PEG to finally construct a type of sorafenib-loaded micelle.72 By co-delivering TG100-115 and sorafenib, a first-line drug for the treatment of advanced liver cancer, the micelles exhibited much better antitumor activity in a Hep-3B-bearing nude mouse model compared to the single-drug treatment.

In addition to the above-mentioned HES-based NPs or micelles, some HES nanocapsules have also been fabricated. HES nanocapsules with surface PEGylation were generated via interface polyaddition and attachment of PEG chains.73 These HES nanocapsules showed potential for functioning as a platform to deliver diagnostic and therapeutic agents. Another project created folic acid-conjugated HES nanocapsules by first fabricating HES nanocapsules with carboxymethylation using an inverse miniemulsion method, and then conjugating them with N\textsubscript{2}-terminated folic acid.62 These HES nanocapsules showed confirmative receptor-mediated targeting capability towards HeLa cells. In view of the many differences observed from these HES-based NPs, their main characteristics are summarised in Table 2 to facilitate their identification.

**Future Perspectives of Hydroxyethyl Starch-Based Nanocarriers**

Based on the above observations, it can be concluded that in recent years, HES has evoked a great deal of research interest in nanocarriers that are intended for delivery of diagnostic and therapeutic agents for anticancer treatments. The reason why

---

### Table 2. HES-based nanoparticles and their characteristics.

| Name of nanoparticles | Name of drug | Responsiveness | Strength | Reference |
|-----------------------|--------------|----------------|----------|-----------|
| DiR/HES-SS-PTX        | PTX          | Redox/Radiation| Combination therapy; Imaging | Li et al.68 |
| HES-SS-DOX@ICG        | DOX          | Redox/Radiation| Combination therapy; Imaging | Yu et al.57 |
| DOX@HES-g-PLA         | DOX          | –              | RES blockade | Yu et al.57 |
| DOX/LY@HES-g-PLA      | DOX          | –              | Overcoming metastasis | Zhou et al.55 |
| DOX/ICG@Gal-HES-PCL   | DOX          | Radiation      | Targeting; Combination therapy; Imaging | Hu et al.54 |
| DOX@HES-PDA           | DOX          | –              | HESylation comparison | Wu et al.53 |
| DOX@iRGD-HES-SS-C18   | DOX          | Redox         | Targeting | Hu et al.51 |
| ICG@HES-OA            | PEITC        | Radiation      | Photodynamic therapy; Combination therapy | Hu et al.66 |
| PyHES-NAC             | DOX          | pH            | Oral delivery | Jong et al.57 |
| HES-CUR               | CUR          | –             | Improved efficiency | Chen et al.59 |
| HES-TG100-115-CDM-PEG | Sorafenib    | –             | Combination therapy | Li and Zhao72 |

**Note:** C18: 1-octadecanethiol; CUR: curcumin; DiR: 1,1-dioctadecyl-3,3,3,3-tetramethyl indotricarbocyanine iodide; DOX: doxorubicin; Gal: galactose; HES: hydroxyethyl starch; ICG: indocyanine green; iRGD: 9-amino acid cyclic peptide; IRG: N-acetyl-cysteine; OA: oleic acid; PCL: polycaprolactone; PDA: polydopamine; PEG: poly(ethylene glycol); PEITC: β-phenylethyl isothiocyanate; PLA: polylactide; PTX: paclitaxel; PyHES: HES intermediate with hydrophobic branches; TG100-115: an exclusive phosphatidylinositol 3-kinase-γ inhibitor; RES: reticuloendothelial system.
HES is so valued and welcomed is due to its specific advantages, mainly high water solubility, excellent in vivo safety, adjustable degradability and chemically-modifiable versatility. It can be seen that the studies on HES-based nanocarriers described above mainly focus on polymeric prodrugs, HES modifications associated with hydrophobic small molecules and self-assembly of prodrugs or modified HES derivatives, while there is obviously less research on HES grafting copolymers and their assembly. HES molecules themselves behave like microspheres with a size of more than ten nanometres in their hydrated state, depending on their molecular weight, mole substitution and substitution pattern. It has been found that HES grafting copolymers can only be assembled into larger NPs so that they are unsuitable as a carrier for nanomedicines, given that the hydrophobic branches on the HES molecules are long or have a high degree of substitution. Hence, it remains a challenge to regulate the length of hydrophobic side chains on the HES molecules and to control the substitution degree of side chains if there are plans to explore more HES grafting copolymers. It is known that HES has a large daily maximum-tolerated dose when used as a plasma substitute. Although HES nanocarriers can be used to increase the dosage of anticancer drugs to some extent due to the high HES tolerance, the drug loading for these nanocarriers still needs to be increased to reduce the cost and to improve the bioavailability of nanomedicines. The above-presented studies reveal that HES nanocarriers have promising potential in delivering diagnostic and therapeutic agents towards cancers. Consequently the development of more HES-associated nanomedicines against cancers, and their active translation into clinical applications, should be encouraged.

Author contributions
RT wrote the draft of manuscript; YW and XY revised and edited the manuscript. All authors approved the final version of this manuscript.

Financial support
This work was financially supported by the National Key Research and Development Program of China (No. 2017YFC1103800).

Acknowledgement
None.

Conflicts of interest statement
The authors declare no competing financial interest.

Data sharing statement
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

1. Aslam, M.; Naveed, S.; Ahmed, A.; Abbas, Z.; Gull, I.; Athar, M. Side effects of chemotherapy in cancer patients and evaluation of patients opinion about starvation based differential chemotherapy. J Cancer Ther. 2014, 5, 817-822.
2. Volk-Draper, L.; Hall, K.; Griggs, C.; Rajput, S.; Kohio, P.; DeNardo, D.; Ran, S. Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. Cancer Res. 2014, 74, 5421-5434.
3. Wang, A. Z.; Langer, R.; Farokhzad, O. C. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012, 63, 185-198.
4. Fang, R.; Liu, M.; Jiang, L. Design of nanoparticle systems by controllable assembly and temporal/spatial regulation. Adv Funct Mater. 2020, 30, 1903351.
5. Harada, A.; Kataoka, K. Supramolecular assemblies of block copolymers in aqueous media as nanocontainers relevant to biological applications. Prog Polym Sci. 2006, 31, 949-982.
6. Rao, R.; Gao, M.; Liu, F.; Guo, X.; Fan, A.; Ding, D.; Kong, D.; Wang, Z.; Zhao, Y. Alleviating the liver toxicity of chemotherapy via ph-responsive hepatoprotective prodrug micelles. ACS Appl Mater Interfaces. 2018, 10, 21836-21846.
7. Wang, Y.; Wang, X.; Deng, F.; Zheng, N.; Liang, Y.; Zhang, H.; He, B.; Dai, W.; Wang, X.; Zhang, Q. The effect of linkers on the self-assembly and anti-tumor efficacy of disulfide-linked doxorubicin drug-drug conjugate nanoparticles. J Control Release. 2018, 279, 136-146.
8. An, X.; Zhu, A.; Luo, H.; Ke, H.; Chen, H.; Zhao, Y. Rational design of multi-stimuli-responsive nanoparticles for precise cancer therapy. ACS Nano. 2016, 10, 5947-5958.
9. Meng, X.; Gao, M.; Deng, J.; Lu, D.; Fan, A.; Ding, D.; Kong, D.; Wang, Z.; Zhao, Y. Self-immolative micellar drug delivery: The linker matters. Nano Res. 2018, 11, 6177-6189.
10. Blanco, E.; Shen, H.; Ferrar, M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015, 33, 941-951.
11. Deng, C.; Jiang, Y.; Cheng, R.; Meng, F.; Zhong, Z. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: Promises, progress and prospects. Nano Today. 2012, 7, 467-480.
12. Liu, Z.; Jiao, Y.; Wang, Y.; Zhou, C.; Zhang, Z. Polysaccharide-based nanoparticles as drug delivery systems. Adv Drug Deliv Rev. 2008, 60, 1650-1662.
13. Goodarzi, N.; Varshochian, R.; Kamalini, G.; Atyabi, F.; Dinavazand, R. A review of polysaccharide cytotoxic drug conjugates for cancer therapy. Carbohydr Polym. 2013, 92, 1280-1293.
14. Westphal, M.; James, M. F.; Kozek-Langenecker, S.; Stocker, R.; Guidet, B.; Van Aken, H. Hydroxystarch stearhicles: different products—different effects. Anesthesiology. 2009, 111, 187-202.
15. Li, D.; Ding, J.; Zhuang, X.; Chen, L.; Chen, X. Drug binding rate regulates the properties of polysaccharide prodrugs. J Mater Chem B. 2016, 4, 5167-5177.
16. Paleos, C. M.; Siderotou, Z.; Tsiourvsa, D. Drug delivery systems based on hydroxystarch. Biocomb. Chem. 2017, 28, 1611-1624.
17. Goszczyński, T. M.; Filip-Pourska, B.; Kempińska, K.; Wietrzyk, J.; Boratyński, J. Hydroxystarch as an effective methotrexate carrier in anticancer therapy. Pharmacol Res Perspect. 2014, 2, e00047.
18. Xie, F.; Pollet, E.; Halley, P. J.; Avérous, L. Starch-based nanobiocomposites. Prog Polym Sci. 2013, 38, 1590-1628.
19. Chen, Q.; Yu, H.; Wang, L.; ul Abidin, Z.; Chen, Y.; Wang, J.; Zhou, W.; Yang, X.; Khan, R. U.; Zhang, H.; Chen, X. Recent progress in chemical modification of starch and its applications. RSC Adv. 2015, 5, 67459-67474.
20. Glover, P. A.; Rudloff, E.; Kirby, R. Hydroxystarch stearhicle: a review of pharmacokinetics, pharmacodynamics, current products, and potential clinical risks, benefits, and use. J Vet Emerg Crit Care (San Antonio). 2014, 24, 642-661.
21. Li, W.; Xiao, X.; Zhang, W.; Zheng, J.; Luo, Q.; Ouyang, S.; Zhang, G. Compositional, morphological, structural and physicochemical properties of starches from seven naked barley cultivars grown in China. Food Res Int. 2014, 58, 7-14.
22. Al, Y.; Jane, J. L. Gelatinization and rheological properties of starch. Starch. 2015, 67, 213-224.
23. Gosch, C. I.; Haase, T.; Wolf, B. A.; Kulicke, W. M. Molar mass distribution and size of hydroxystarch stearhicle fractions obtained by
continuous polymer fractionation. Starke. 2002, 54, 375–384.
24. Boldt, J. Modern rapidly degradable hydroxyethyl starches: current concepts. Anesth Analg. 2009, 108, 1574–1582.
25. Metcalf, W.; Papadopoulos, A.; Tufaro, R.; Barth, A. A clinical physiologic study of hydroxyethyl starch. Surg Gynecol Obstet. 1970, 131, 255–267.
26. Besheer, A.; Hause, G.; Kressler, J.; Mäder, K. Hydrophobically modified hydroxyethyl starch: synthesis, characterization, and aqueous self-assembly into nano-sized polymeric micelles and vesicles. Biomacromolecules. 2007, 8, 359–367.
27. Yu, C.; Zhou, Q.; Xiao, F.; Li, Y.; Hu, H.; Wan, Y.; Li, Z.; Yang, X. Enhancing doxorubicin delivery toward tumor by hydroxyethyl starch-g-polylactide partner nanocarriers. ACS Appl Mater Interfaces. 2017, 9, 10481–10493.
28. Li, Y.; Wu, Y.; Chen, J.; Wan, J.; Xiao, C.; Guan, J.; Song, X.; Li, S.; Zhang, M.; Cui, H.; Li, T.; Yang, X.; Li, Z.; Zhang, Y. A simple glutathione-responsive turn-on theranostic nanoparticle for dual-modal imaging and chemo-photothermal combination therapy. Nano Lett. 2019, 19, 5806–5817.
29. Li, Y.; Hu, H.; Zhou, Q.; Ao, Y.; Xiao, C.; Wan, J.; Wan, Y.; Hu, H.; Li, Z.; Yang, X. α-Amylase- and redox-responsive nanoparticles for tumor-targeted drug delivery. ACS Appl Mater Interfaces. 2017, 9, 19215–19230.
30. Hu, H.; Li, Y.; Zhou, Q.; Ao, Y.; Yu, C.; Wan, Y.; Xu, H.; Li, Z.; Yang, X. Redox-sensitive hydroxyethyl starch-doxorubicin conjugate for tumor targeted drug delivery. ACS Appl Mater Interfaces. 2016, 8, 30833–30844.
31. Hu, H.; Wan, J.; Huang, X.; Tang, Y.; Xiao, C.; Xu, H.; Yang, X.; Li, Z.; iRGD-decorated reduction-responsive nanoclusters for targeted drug delivery. Nanoscale. 2018, 10, 10154–10157.
32. Xiao, C.; Hu, H.; Yang, H.; Li, S.; Zhou, H.; Ruan, J.; Zhu, Y.; Yang, X.; Li, Z. Colloidal hydroxyethyl starch for tumor-targeted platinum delivery. Nanoscale Adv. 2019, 1, 1002–1012.
33. Wu, H.; Hu, H.; Wan, J.; Li, Y.; Wu, Y.; Tang, Y.; Xiao, C.; Xu, H.; Yang, X.; Li, Z. Hydroxyethyl starch stabilized polydopamine nanoparticles for cancer chemotherapy. Chem Eng J. 2018, 349, 129–145.
34. Liu, Q.; Yang, X.; Xu, H.; Pan, K.; Yang, Y. Novel nanomicelles originating from hydroxyethyl starch-g-polylactide and their release behavior of doce Taxel modulated by the PLA chain length. Eur Polym J. 2013, 49, 3522–3529.
35. Zhou, Q.; Li, Y.; Zhu, Y.; Yu, C.; Jia, H.; Bao, B.; Hu, H.; Xiao, C.; Zhang, J.; Zeng, X.; Wan, Y.; Xu, H.; Li, Z.; Yang, X. Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy. J Control Release. 2018, 275, 67–77.
36. Larson, D.; Ghandehari, H. Polymeric conjugates for drug delivery. Chem Mater. 2012, 24, 840–853.
37. Zhou, P.; Li, Z.; Chau, Y. Synthesis, characterization, and in vivo evaluation of poly(ethylene oxide-co-glycidol)-platinate conjugate. Eur J Pharm Sci. 2010, 41, 464–472.
38. Lipinscki, C. Poor aqueous solubility—an industry wide problem in drug discovery. Am Pharm Rev. 2002, 5, 82–85.
39. Zhu, C.; Liu, L.; Yang, Q.; Lv, F.; Wang, S. Water-soluble conjugated polymers for imaging, diagnosis, and therapy. Chem Rev. 2012, 112, 4687–4735.
40. Luo, Q.; Wang, P.; Miao, Y.; He, H.; Tang, X. A novel 5-fluorouracil prodrug using hydroxyethyl starch as a macromolecular carrier for sustained release. Carbohydr Polym. 2012, 87, 2642–2647.
41. Zhou, Z.; Ma, X.; Jin, E.; Tang, J.; Sui, M.; Shen, Y.; Van Kirk, E. A.; Murdoch, W. J.; Radosz, M. Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery. Biomaterials. 2013, 34, 5722–5735.
42. Jana, S.; Mandlekar, S.; Marathe, P. Prodrug design to improve pharmacokinetic and drug delivery properties: challenges to the discovery scientists. Curr Med Chem. 2010, 17, 3874–3908.
43. Dong, Z.; Li, Q.; Guo, D.; Shu, Y.; Polli, J. E. Synthesis and evaluation of bile acid-ribavirin conjugates as prodrugs to target the liver. J Pharm Sci. 2015, 104, 2864–2876.
44. Lelieveldt, L.; Kristyanto, H.; Pruijn, G. J. M.; Scherer, H. U.; Toes, R. E. M.; Bonger, K. M. Sequential prodrug strategy to target and eliminate ACPA-selective autoreactive B cells. Mol Pharm. 2018, 15, 5565–5573.
45. Li, D.; Feng, X.; Chen, L.; Ding, J.; Chen, X. One-step synthesis of targeted acid-labile polysaccharide prodrug for efficiently intracellular drug delivery. ACS Biomater Sci Eng. 2018, 4, 539–546.
46. Zhao, K.; Li, D.; Xu, W.; Ding, J.; Jiang, W.; Li, M.; Wang, C.; Chen, X. Targeted hydroxyethyl starch prodrug for inhibiting the growth and metastasis of prostate cancer. Biomaterials. 2017, 116, 82–94.
47. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor-tropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6587–6592.
48. Zhou, Q.; Shao, S.; Wang, J.; Xu, C.; Xiang, J.; Piao, Y.; Zhou, Z.; Yu, Q.; Tang, J.; Liu, X.; Gan, Z.; Mo, R.; Gu, Z.; Shen, Y. Enzyme-activatable polymer-drug conjugate augments tumour penetration and treatment efficacy. Nat Nanotechnol. 2019, 14, 799–809.
49. Li, G.; Li, Y.; Tang, Y.; Zhang, Y.; Zhang, Y.; Yin, T.; Xu, H.; Cai, C.; Tang, X. Hydroxyethyl starch conjugates for improving the stability, pharmacokinetic behavior and antitumor activity of 10-hydroxy camptothecin. Int J Pharm. 2014, 471, 234–244.
50. Li, G.; Zhao, M.; Zhao, L. Well-defined hydroxyethyl starch-10-hydroxy camptothecin super macromolecule conjugate: cytotoxicity, pharmacodynamics research, tissue distribution test and intravenous injection safety assessment. Drug Deliv. 2016, 23, 2860–2868.
51. Zhu, Y.; Yao, X.; Chen, X.; Chen, L. pH-sensitive hydroxyethyl starch-doxorubicin conjugates as antitumor prodrugs with enhanced anticancer efficacy. J Appl Polym Sci. 2015, 132, 42778.
Hydroxyethyl starch used for anticancer nanomedicines

59. Veronese, F. M. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001, 22, 405-417.

60. Nichols, J. W.; Bae, Y. H. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today. 2012, 7, 606-618.

61. Lemarchand, C.; Gref, R.; Couvreur, P. Polysaccharide-decorated nanoparticles. Eur J Pharm Biopharm. 2004, 58, 327-341.

62. Baier, G.; Baumann, D.; Siebert, J. M.; Musyanovych, A.; Mailänder, V.; Landfester, K. Suppressing unspecific cell uptake for targeted delivery using hydroxyethyl starch nanocapsules. Biomacromolecules. 2012, 13, 2704-2715.

63. Noga, M.; Edinger, D.; Kläger, R.; Wegner, S. V.; Spatz, J. P.; Wagner, E.; Winter, G.; Besheer, A. The effect of molar mass and degree of hydroxyethylation on the controlled shielding and deshielding of hydroxyethyl starch-coated polyplexes. Biomaterials. 2013, 34, 2530-2538.

64. Liebner, R.; Mathaes, R.; Meyer, M.; Hey, T.; Winter, G.; Besheer, A. Protein HESylation for half-life extension: synthesis, characterization and pharmacokinetics of HESylated anakinra. Eur J Pharm Biopharm. 2014, 87, 378-385.

65. Liu, Y.; Ai, K.; Lu, L. Polydopamine and its derivative materials: synthesis and promising applications in energy, environmental, and biomedical fields. Chem Rev. 2014, 114, 5057-5115.

66. Hu, H.; Chen, J.; Yang, H.; Huang, X.; Wu, H.; Wu, Y.; Li, F.; Yi, Y.; Xiao, C.; Li, Y.; Tang, Y.; Li, Z.; Zhang, B.; Yang, X. Potentiating photodynamic therapy of ICG-loaded nanoparticles by depleting GSH with PEITC. Nanoscale. 2019, 11, 6384-6393.

67. Jong, K.; Ju, B.; Zhang, S. Synthesis of pH-responsive N-acetyl-cysteine modified starch derivatives for oral delivery. J Biomater Sci Polym Ed. 2017, 28, 1525-1537.

68. Besheer, A.; Vogel, J.; Glanz, D.; Kressler, J.; Groth, T.; Mäder, K. Characterization of PLGA nanospheres stabilized with amphiphilic polymers: hydrophobically modified hydroxyethyl starch vs pluronic. Mol Pharm. 2009, 6, 407-415.

69. Chen, S.; Wu, J.; Tang, Q.; Xu, C.; Huang, Y.; Huang, D.; Luo, F.; Wu, Y.; Yan, F.; Weng, Z.; Wang, S. Nano-micelles based on hydroxyethyl starch-curcumin conjugates for improved stability, antioxidant and anticancer activity of curcumin. Carbohydr Polym. 2020, 228, 115398.

70. Naksuriya, O.; Okonogi, S.; Schifflers, R. M.; Hennink, W. E. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014, 35, 3365-3383.

71. Serban, D.; Leng, J.; Chered, D. H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ Res. 2008, 102, 1350-1358.

72. Li, G.; Zhao, L. Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment. Drug Deliv. 2019, 26, 756-764.

73. Kang, B.; Okwieka, P.; Schöttler, S.; Seifert, O.; Kontermann, R. E.; Pfizenmaier, K.; Musyanovych, A.; Meyer, R.; Diken, M.; Sahin, U.; Mailänder, V.; Wurm, F. R.; Landfester, K. Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. Biomaterials. 2015, 49, 125-134.